| Literature DB >> 31807289 |
Nestor Oliva-Damaso1, Elena Oliva-Damaso2, Jose C Rodriguez-Perez2, Juan Payan1.
Abstract
In chronic kidney disease (CKD), referral to nephrology is based on Kidney Disease: Improving Global Outcomes 2012 guidelines and is generally indicated when the estimated glomerular filtration rate (eGFR) is <30 mL/min/1.73 m2 or when there is a rapid decline of eGFR, elevated urinary albumin:creatinine ratio (>300 mg/g) or other 'alert' signs such as the presence of urinary red blood cell casts. Since eGFR declines with ageing in otherwise healthy individuals, we propose that the eGFR threshold for nephrology referral should be adjusted according to age. According to current recommendations, young patients without rapidly progressing CKD are referred more often to nephrology when CKD is more severe, compared with age-matched controls with normal eGFRs, than elderly CKD patients. In this commentary, we discuss the age factor and other specific situations not considered in current guidelines for nephrology referral of CKD patients.Entities:
Keywords: chronic kidney disease; nephrology referral; phone application; smartphone app
Year: 2019 PMID: 31807289 PMCID: PMC6885667 DOI: 10.1093/ckj/sfz115
Source DB: PubMed Journal: Clin Kidney J ISSN: 2048-8505
Current criteria of nephrology referral in CKD (KDIGO 2012) [1]
|
|
| AKI with abrupt sustained decrease in GFR |
| GFR <30 mL/min/1.73 m2 (GFR categories G4–G5) |
| A consistent finding of significant albuminuria (ACR ≥300 mg/g or AER ≥300 mg/24 h, approximately equivalent to PCR ≥500 mg/g or PER ≥500 mg/24 h) |
| Progression of CKD |
| Urinary red cell casts, RBC >20 per high-power field sustained and not readily explained |
| CKD and hypertension refractory to treatment with four or more antihypertensive agents |
| Persistent abnormalities of serum potassium level |
| Recurrent or extensive nephrolithiasis |
| Hereditary kidney disease |
ACR, albumin:creatinine ratio; AER, albumin excretion rate; PCR, protein:creatinine ratio; PER, protein excretion rate; RBC, red blood cell.
FIGURE 1Normal age-related changes in GFR assessed by inulin clearance in the landmark studies by Davies and Shock [8]. Considering GFR as the reason for nephrology referral, current criteria, according to KDIGO guidelines, require eGFR of <30 mL/min/1.73 m2 for referral in stable CKD patients. However, the relative loss of eGFR, compared with healthy age-matched controls, that would warrant referral is greater in young than in elderly CKD patients. We suggest adjusting eGFR thresholds for nephrology referral in younger individuals, which would match the relative loss of eGFR versus age-matched controls in current recommendations for elderly CKD patients. We propose new eGFR thresholds of <45 mL/min/1.73 m2 for patients 40–60 years of age and <60 mL/min/1.73 m2 for those <40 years of age.
Proposed criteria for referral to nephrology in CKD
| Criteria |
| AKI with abrupt sustained decrease in GFR |
|
|
|
|
|
|
| A consistent finding of significant albuminuria (ACR ≥300 mg/g or AER ≥300 mg/24 h, approximately equivalent to PCR ≥500 mg/g or PER ≥500 mg/24 h) |
| Progression of CKD |
| Urinary red cell casts, RBC >20 per high-power field sustained and not readily explained |
| CKD and hypertension refractory to treatment with four or more antihypertensive agents |
| Persistent abnormalities of serum potassium level |
| Recurrent or extensive nephrolithiasis |
| Hereditary kidney disease |
|
|
|
|
Changes proposed are highlighted in bold.
ACR, albumin:creatinine ratio; AER, albumin excretion rate; PCR, protein:creatinine ratio; PER, protein excretion rate; RBC, red blood cell.
FIGURE 2The smartphone app NefroConsultor. Referral to nephrology can be impeded by numerous factors, including physicians’ lack of knowledge of guideline recommendations for timing and indications of nephrology referral. Smartphone apps can overcome this hindering factor by providing user-friendly in-built calculators. Additionally, these apps allow exploration of multiple alternative patient scenarios and enable guideline developers to assess the real impact of guidelines being developed on different patient types.